Tests a DNA-based method to diagnose thyroid nodules and thyroid cancer
Tests DNA methylation patterns from thyroid needle biopsies in adults with thyroid nodules.
Plain-language title generated from the registry record
Registry title: Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Key facts
- Where
- Duarte, United StatesSee the site
Where in United States
- City of Hope Medical CenterDuarte, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- City of Hope Medical Center
- Trial code
- NCT05229341
- Record updated
- 5 November 2026
- Original description
This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.Read full original descriptionShow less
Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules
This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.
Inclusion: Patients without impaired decision-making capacity and who are undergoing needle biopsies for thyroid nodule diagnosis; Over the age of 18; Any gender, race and ethnicity; Patients must provide informed consent prior to use of their tissues and clinical data.
Exclusion: Children are excluded from the study, since the biology of children thyroid nodules is different from adults.